294 related articles for article (PubMed ID: 27183546)
21. Intraocular pressure outcome of patients with fluocinolone acetonide intravitreal implant for noninfectious uveitis.
Bollinger K; Kim J; Lowder CY; Kaiser PK; Smith SD
Ophthalmology; 2011 Oct; 118(10):1927-31. PubMed ID: 21652079
[TBL] [Abstract][Full Text] [Related]
22. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study.
Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH
Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472
[TBL] [Abstract][Full Text] [Related]
23. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN
Augustin AJ; Bopp S; Fechner M; Holz F; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer M; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H; Gentsch D
Eur J Ophthalmol; 2020 Mar; 30(2):382-391. PubMed ID: 30884972
[TBL] [Abstract][Full Text] [Related]
24. Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN
Syed YY
Drugs; 2017 Apr; 77(5):575-583. PubMed ID: 28283896
[TBL] [Abstract][Full Text] [Related]
25. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results.
Ramchandran RS; Fekrat S; Stinnett SS; Jaffe GJ
Am J Ophthalmol; 2008 Aug; 146(2):285-291. PubMed ID: 18533125
[TBL] [Abstract][Full Text] [Related]
26. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.
Fusi-Rubiano W; Mukherjee C; Lane M; Tsaloumas MD; Glover N; Kidess A; Denniston AK; Palmer HE; Manna A; Morjaria R
BMC Ophthalmol; 2018 Feb; 18(1):62. PubMed ID: 29486754
[TBL] [Abstract][Full Text] [Related]
27. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.
Campochiaro PA; Brown DM; Pearson A; Ciulla T; Boyer D; Holz FG; Tolentino M; Gupta A; Duarte L; Madreperla S; Gonder J; Kapik B; Billman K; Kane FE;
Ophthalmology; 2011 Apr; 118(4):626-635.e2. PubMed ID: 21459216
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants.
Yang Y; Bailey C; Holz FG; Eter N; Weber M; Baker C; Kiss S; Menchini U; Ruiz Moreno JM; Dugel P; Lotery A;
Eye (Lond); 2015 Sep; 29(9):1173-80. PubMed ID: 26113503
[TBL] [Abstract][Full Text] [Related]
29. Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience.
Fallico M; Maugeri A; Lotery A; Longo A; Bonfiglio V; Russo A; Avitabile T; Furino C; Cennamo G; Barchitta M; Agodi A; Marolo P; Ventre L; Caselgrandi P; Reibaldi M
Sci Rep; 2021 Feb; 11(1):4800. PubMed ID: 33637841
[TBL] [Abstract][Full Text] [Related]
30. Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results.
Jain N; Stinnett SS; Jaffe GJ
Ophthalmology; 2012 Jan; 119(1):132-7. PubMed ID: 21924503
[TBL] [Abstract][Full Text] [Related]
31. Prophylactic selective laser trabeculoplasty in the prevention of intraocular pressure elevation after intravitreal triamcinolone acetonide injection.
Bozkurt E; Kara N; Yazici AT; Yuksel K; Demirok A; Yilmaz OF; Demir S
Am J Ophthalmol; 2011 Dec; 152(6):976-981.e2. PubMed ID: 21861972
[TBL] [Abstract][Full Text] [Related]
32. Ocular, Visual, and Anatomical Outcomes in Eyes Requiring Incisional Intraocular Pressure-Lowering Surgery Following the 0.19-mg Fluocinolone Acetonide Intravitreal Implant.
Eichenbaum D; Gonzalez VH; Roth D; Fortun J; Radcliffe NM; Cutino A; Kasper J; Coughlin BA; Arevalo JF
Ophthalmic Surg Lasers Imaging Retina; 2024 Jan; 55(1):22-23. PubMed ID: 38189802
[TBL] [Abstract][Full Text] [Related]
33. Risk factors associated with intraocular pressure increase in patients with uveitis treated with the fluocinolone acetonide implant.
Parekh A; Srivastava S; Bena J; Albini T; Nguyen QD; Goldstein DA
JAMA Ophthalmol; 2015 May; 133(5):568-73. PubMed ID: 25719937
[TBL] [Abstract][Full Text] [Related]
34. Fluocinolone acetonide intravitreal implant (Iluvien®): in diabetic macular oedema.
Sanford M
Drugs; 2013 Feb; 73(2):187-93. PubMed ID: 23335133
[TBL] [Abstract][Full Text] [Related]
35. Fluocinolone acetonide implantable device for diabetic retinopathy.
Schwartz SG; Flynn HW
Curr Pharm Biotechnol; 2011 Mar; 12(3):347-51. PubMed ID: 20939799
[TBL] [Abstract][Full Text] [Related]
36. The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema.
Cicinelli MV; Rosenblatt A; Grosso D; Zollet P; Capone L; Rabiolo A; Lattanzio R; Loewenstein A; Bandello F;
Eye (Lond); 2021 Dec; 35(12):3232-3242. PubMed ID: 33479485
[TBL] [Abstract][Full Text] [Related]
37. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema.
Cunha-Vaz J; Ashton P; Iezzi R; Campochiaro P; Dugel PU; Holz FG; Weber M; Danis RP; Kuppermann BD; Bailey C; Billman K; Kapik B; Kane F; Green K;
Ophthalmology; 2014 Oct; 121(10):1892-903. PubMed ID: 24935282
[TBL] [Abstract][Full Text] [Related]
38. Selective laser trabeculoplasty for intraocular pressure elevation after intravitreal triamcinolone acetonide injection.
Pizzimenti JJ; Nickerson MM; Pizzimenti CE; Kasten-Aker AG
Optom Vis Sci; 2006 Jul; 83(7):421-5. PubMed ID: 16840867
[TBL] [Abstract][Full Text] [Related]
39. The effect of selective laser trabeculoplasty on intraocular pressure in patients with intravitreal steroid-induced elevated intraocular pressure.
Rubin B; Taglienti A; Rothman RF; Marcus CH; Serle JB
J Glaucoma; 2008; 17(4):287-92. PubMed ID: 18552614
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy.
Meireles A; Goldsmith C; El-Ghrably I; Erginay A; Habib M; Pessoa B; Coelho J; Patel T; Tadayoni R; Massin P; Atorf J; Augustin AJ
Eye (Lond); 2017 May; 31(5):684-690. PubMed ID: 28085139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
